CHF47.65
0.74%
SIX Swiss Exchange, Apr 25, 05:31 pm CET
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

COSMO Pharmaceuticals Stock price

CHF47.65
-7.65 13.83% 1M
-23.25 32.79% 6M
-16.05 25.20% YTD
-24.45 33.91% 1Y
-8.75 15.51% 3Y
-26.35 35.61% 5Y
-130.35 73.23% 10Y
SIX Swiss Exchange, Closing price Fri, Apr 25 2025
+0.35 0.74%
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

Key metrics

Market capitalization CHF763.12m
Enterprise Value CHF637.37m
P/E (TTM) P/E ratio 6.02
EV/FCF (TTM) EV/FCF 4.27
EV/Sales (TTM) EV/Sales 2.51
P/S ratio (TTM) P/S ratio 3.00
P/B ratio (TTM) P/B ratio 1.63
Dividend yield 4.08%
Last dividend (FY25) CHF1.95
Revenue growth (TTM) Revenue growth 182.25%
Revenue (TTM) Revenue CHF254.22m
EBIT (operating result TTM) EBIT CHF138.59m
Free Cash Flow (TTM) Free Cash Flow CHF149.20m
EPS (TTM) EPS CHF7.91
P/E forward 225.25
P/S forward 4.81
EV/Sales forward 4.02
Show more

Is COSMO Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

COSMO Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a COSMO Pharmaceuticals forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a COSMO Pharmaceuticals forecast:

Buy
100%

Financial data from COSMO Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
254 254
182% 182%
100%
- Direct Costs 43 43
13% 13%
17%
211 211
307% 307%
83%
- Selling and Administrative Expenses 23 23
51% 51%
9%
- Research and Development Expense 38 38
108% 108%
15%
150 150
711% 711%
59%
- Depreciation and Amortization 12 12
15% 15%
5%
EBIT (Operating Income) EBIT 139 139
2,861% 2,861%
55%
Net Profit 127 127
2,816% 2,816%
50%

In millions CHF.

Don't miss a Thing! We will send you all news about COSMO Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Head office Netherlands
CEO Giovanni Napoli
Employees 321
Founded 2016
Website www.cosmopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today